{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T14:21:31Z","timestamp":1782051691329,"version":"3.54.5"},"reference-count":89,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clbc.2026.01.004","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:31:40Z","timestamp":1768005100000},"page":"54-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Breast Cancer Vaccines: A Review of Emerging Opportunities and Persistent Challenges"],"prefix":"10.1016","volume":"26","author":[{"given":"I. Jeya","family":"Sheela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Amala","family":"Jeya Ranchani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravindh","family":"Murali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8948-6729","authenticated-orcid":false,"given":"H.","family":"Premkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2026.01.004_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2026.01.004_bib0002","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2026.01.004_bib0003","doi-asserted-by":"crossref","DOI":"10.2196\/53969","article-title":"Unveiling sociocultural barriers to breast cancer awareness among the South Asian Population: case study of Bangladesh and West Bengal, India","volume":"12","author":"Hamid","year":"2025","journal-title":"JMIR Hum Factors"},{"key":"10.1016\/j.clbc.2026.01.004_bib0004","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4143\/crt.2025.263","article-title":"Prediction of cancer incidence and mortality in Korea, 2025","volume":"57","author":"Jung","year":"2025","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.01.004_bib0005","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/ajco.13958","article-title":"Incidence, mortality, survival, and disease burden of breast cancer in China compared to other developed countries","volume":"19","author":"Tao","year":"2023","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.01.004_bib0006","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12885-015-1098-z","article-title":"Residential environment and breast cancer incidence and mortality: a systematic review and meta-analysis","volume":"15","author":"Akinyemiju","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2026.01.004_bib0007","first-page":"79","author":"Ragaz","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2026.01.004_bib0008","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/10105395241306488","article-title":"Epidemiology of Cancer in the Fiji Islands: 2010 to 2018","volume":"37","author":"Naidu","year":"2025","journal-title":"Asia Pac J Public Health"},{"key":"10.1016\/j.clbc.2026.01.004_bib0009","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000040784","article-title":"Cutting-edge and topical issues in the treatment of breast cancer with traditional Chinese medicine based on CiteSpace bibliometric analysis","volume":"103","author":"Chai","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.clbc.2026.01.004_bib0010","unstructured":"Kresge K.J. Cervical cancer vaccines. Introduction of vaccines that prevent cervical cancer and genital warts may fore-shadow implementation and acceptability issues for a future AIDS vaccines. IAVI Rep. 2005;9(5).1-5."},{"key":"10.1016\/j.clbc.2026.01.004_bib0011","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/14760584.2024.2303015","article-title":"Neoadjuvant personalized cancer vaccines: the final frontier?","volume":"23","author":"Richard","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.clbc.2026.01.004_bib0012","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/14760584.2021.1951246","article-title":"Development of neoantigens: from identification in cancer cells to application in cancer vaccines","volume":"21","author":"Ebrahimi","year":"2022","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.clbc.2026.01.004_bib0013","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/14760584.2022.2021884","article-title":"Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence","volume":"21","author":"Abbaspour","year":"2022","journal-title":"Expert Review of Vaccines"},{"key":"10.1016\/j.clbc.2026.01.004_bib0014","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/17425247.2023.2168640","article-title":"Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy","volume":"20","author":"Wu","year":"2023","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.clbc.2026.01.004_bib0015","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/14760584.2023.2232450","article-title":"Emergence of mRNA vaccines in the management of cancer","volume":"22","author":"Mohamad Razif","year":"2023","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.clbc.2026.01.004_bib0016","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438592","article-title":"State-of-the-art advancements on cancer vaccines and biomarkers","volume":"44","author":"Strum","year":"2024","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"10.1016\/j.clbc.2026.01.004_bib0017","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ijc.20429","article-title":"Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature","volume":"112","author":"Calderon-Margalit","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clbc.2026.01.004_bib0018","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1472-6874-10-28","article-title":"Risk-reducing strategies for women carrying brca1\/2 mutations with a focus on prophylactic surgery","volume":"10","author":"Salhab","year":"2010","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.clbc.2026.01.004_bib0019","doi-asserted-by":"crossref","DOI":"10.1158\/1055-9965.1989.13.12","article-title":"Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation","volume":"13","author":"Wainberg","year":"2004","journal-title":"Cancer Epidemiolo Biomarkers Prev"},{"key":"10.1016\/j.clbc.2026.01.004_bib0020","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1001\/jama.1997.03540360065034","article-title":"Recommendations for follow-up care of individuals with an inherited predisposition to cancer","volume":"277","author":"Burke","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2026.01.004_bib0021","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/ijc.21273","article-title":"Effect of pregnancy as a risk factor for breast cancer in BRCA1 \/BRCA2 mutation carriers","volume":"117","author":"Cullinane","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clbc.2026.01.004_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120189","article-title":"Worse breast cancer prognosis of BRCA1\/BRCA2 mutation carriers: what\u2019s the Evidence? A systematic review with meta-analysis","volume":"10","author":"van den Broek","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2026.01.004_bib0023","doi-asserted-by":"crossref","first-page":"407","DOI":"10.54097\/3m9zjy95","article-title":"Comparison of traditional treatments and therapeutic vaccines for breast cancer","volume":"102","author":"Zhou","year":"2024","journal-title":"Highl Sci Eng Technol"},{"key":"10.1016\/j.clbc.2026.01.004_bib0024","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.54097\/6mztmd30","article-title":"Therapeutic vaccines in breast cancer","volume":"74","author":"Zhou","year":"2023","journal-title":"Highl Sci Eng Technol"},{"key":"10.1016\/j.clbc.2026.01.004_bib0025","series-title":"International Conference on Modern Medicine and Global Health (ICMMGH 2023)","first-page":"86","article-title":"Breast cancer vaccine: analysis of potential therapeutic vaccines and effects","author":"Ji","year":"2023"},{"issue":"8","key":"10.1016\/j.clbc.2026.01.004_bib0026","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3390\/vaccines10081249","article-title":"Peptide-based vaccines in clinical phases and new potential therapeutic targets as a new approach for breast cancer: a review","volume":"10","author":"Nicolas-Morales","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.clbc.2026.01.004_bib0027","article-title":"Recent progress on therapeutic vaccines for breast cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2026.01.004_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/or.2025.1541326","article-title":"Advancements and challenges in personalized neoantigen-based cancer vaccines","volume":"19","author":"Singh","year":"2025","journal-title":"Oncol Rev"},{"issue":"1","key":"10.1016\/j.clbc.2026.01.004_bib0030","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev-cancerbio-060820-111701","article-title":"Personal neoantigen vaccines for the treatment of cancer","volume":"5","author":"Shetty","year":"2021","journal-title":"Annual Review of Cancer Biology"},{"key":"10.1016\/j.clbc.2026.01.004_bib0031","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10238-024-01436-7","article-title":"Personalized neoantigen cancer vaccines: current progression, challenges and a bright future","volume":"24","author":"Wu","year":"2024","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.clbc.2026.01.004_bib0032","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3390\/vaccines10060945","article-title":"Characterization of the protective immune responses conferred by recombinant BCG overexpressing components of mycobacterium tuberculosis sec protein export system","volume":"10","author":"Nisa","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.clbc.2026.01.004_bib0033","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s12272-017-0969-z","article-title":"Vaccine adjuvants: smart components to boost the immune system","volume":"40","author":"Bastola","year":"2017","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.clbc.2026.01.004_bib0034","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1021\/acsnano.3c03352","article-title":"A trinity nano-vaccine system with spatiotemporal immune effect for the adjuvant cancer therapy after radiofrequency ablation","volume":"18","author":"Li","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.clbc.2026.01.004_bib0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00284-023-03597-2","article-title":"Enhancing Immunological memory: unveiling booster doses to bolster vaccine efficacy against evolving SARS-CoV-2 mutant variants","volume":"81","author":"Samanta","year":"2024","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.clbc.2026.01.004_bib0036","doi-asserted-by":"crossref","DOI":"10.4110\/in.2019.19.e37","article-title":"Aging and the immune system: the impact of immunosenescence on viral infection, immunity and vaccine immunogenicity","volume":"19","author":"Oh","year":"2019","journal-title":"Immune Netw"},{"key":"10.1016\/j.clbc.2026.01.004_bib0037","article-title":"Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy","volume":"118","author":"Wang","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clbc.2026.01.004_bib0038","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3390\/v14050862","article-title":"Fraternal twins: the enigmatic role of the immune system in Alphaherpesvirus pathogenesis and latency and its impacts on vaccine efficacy","volume":"14","author":"Rouse","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.clbc.2026.01.004_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1240926","article-title":"Editorial: strategies to overcome tumor evasion and resistance to immunotherapies by targeting immune suppressor cells","volume":"13","author":"Saida","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2026.01.004_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1116016","article-title":"Strategies to overcome myeloid cell induced immune suppression in the tumor microenvironment","volume":"13","author":"Cao","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2026.01.004_bib0041","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3390\/pharmaceutics14071344","article-title":"Nanotechnology-based siRNA delivery systems to overcome tumor immune evasion in cancer immunotherapy","volume":"14","author":"Deng","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clbc.2026.01.004_bib0042","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.70631","article-title":"Harnessing epigenetic mechanisms to overcome immune evasion in cancer: the current strategies and future directions","author":"Panda","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.clbc.2026.01.004_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.719091","article-title":"Reversing epigenetic gene silencing to overcome immune evasion in CNS malignancies","volume":"11","author":"Ratnam","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2026.01.004_bib0044","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s12276-023-01014-z","article-title":"Histone modifications in drug-resistant cancers: from a cancer stem cell and immune evasion perspective","volume":"55","author":"Jin","year":"2023","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.clbc.2026.01.004_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000543806","article-title":"Multi-Targeting CAR-T cell strategies to overcome immune evasion in lymphoid and myeloid malignancies","author":"Peter","year":"2025","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.clbc.2026.01.004_bib0046","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12935-023-03158-4","article-title":"Single-cell RNA sequencing in cancer research: discovering novel biomarkers and therapeutic targets for immune checkpoint blockade","volume":"23","author":"Sun","year":"2023","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.clbc.2026.01.004_bib0047","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.2174\/0113894501320281240822052657","article-title":"Revolutionizing skin cancer treatment: the rise of PD-1\/PDL-1 and CTLA-4 as key therapeutic targets","volume":"25","author":"Sharma","year":"2024","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.clbc.2026.01.004_bib0048","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3892\/ol.2024.14700","article-title":"PI3K\/AKT\/mTOR and PD1\/CTLA4\/CD28 pathways as key targets of cancer immunotherapy (review)","volume":"28","author":"Wang","year":"2024","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clbc.2026.01.004_bib0049","first-page":"5","article-title":"Cell death pathways: molecular mechanisms and therapeutic targets for cancer","author":"Wang","year":"2024","journal-title":"MedComm (Beijing)"},{"key":"10.1016\/j.clbc.2026.01.004_bib0050","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41417-024-00761-z","article-title":"Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers","volume":"31","author":"Liang","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.clbc.2026.01.004_bib0051","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-024-02205-6","article-title":"Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy","volume":"24","author":"Huang","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clbc.2026.01.004_bib0052","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/13543784.2022.2009456","article-title":"Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects","volume":"31","author":"Rizzo","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clbc.2026.01.004_bib0053","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s11864-023-01069-0","article-title":"Immunotherapy for metastatic triple negative breast cancer: current paradigm and future approaches","volume":"24","author":"Geurts","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.clbc.2026.01.004_bib0054","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/13543784.2022.2054326","article-title":"CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress","volume":"31","author":"Corti","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clbc.2026.01.004_bib0055","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12609-024-00552-3","article-title":"New vaccine therapy for triple-negative breast cancer","volume":"16","author":"Harris","year":"2024","journal-title":"Curr Breast Cancer Rep"},{"key":"10.1016\/j.clbc.2026.01.004_bib0056","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12032-024-02542-y","article-title":"Understanding the chemistry & pharmacology of antibody\u2013drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives","volume":"41","author":"Sawant","year":"2024","journal-title":"Med Oncol"},{"key":"10.1016\/j.clbc.2026.01.004_bib0057","doi-asserted-by":"crossref","first-page":"175","DOI":"10.54254\/2753-8818\/57\/20241307","article-title":"Study on antibody-conjugated drugs and targeted therapy for triple-negative breast cancer","volume":"57","author":"Chen","year":"2024","journal-title":"Theor Nat Sci"},{"key":"10.1016\/j.clbc.2026.01.004_bib0058","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/0115680096280750240123054936","article-title":"Insights into the emerging therapeutic targets of triple-negative breast cancer","volume":"25","author":"Varshini","year":"2025","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.clbc.2026.01.004_bib0059","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/pharmaceutics14020398","article-title":"Lipid nanoparticle delivery systems to enable mRNA-based therapeutics","volume":"14","author":"Semple","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clbc.2026.01.004_bib0060","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3390\/pharmaceutics16020247","article-title":"Maltodextrin-nanoparticles as a delivery system for nasal vaccines: a review article","volume":"16","author":"Fasquelle","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clbc.2026.01.004_bib0061","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/15583720701455020","article-title":"Recent advances in liposome-based nanoparticles for antigen delivery","volume":"47","author":"Yan","year":"2007","journal-title":"Polymer Rev"},{"key":"10.1016\/j.clbc.2026.01.004_bib0062","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-LB431","article-title":"Abstract LB431: Direct comparison of focal adhesion kinase (FAK) therapeutic modalities in cancer: Kinase, FAT, and PROTAC","volume":"84","author":"Reyes","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2026.01.004_bib0063","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.18203\/2349-2902.isj20211826","article-title":"Comparison of various diagnostic and therapeutic modalities of undescended testis","volume":"8","author":"Swami","year":"2021","journal-title":"Int Surg J"},{"key":"10.1016\/j.clbc.2026.01.004_bib0064","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10238-024-01520-y","article-title":"Bispecific antibodies in clinical practice: understanding recent advances and current place in cancer treatment landscape","volume":"25","author":"Verma","year":"2024","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.clbc.2026.01.004_bib0065","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1158\/1535-7163.MCT-19-0007","article-title":"Preclinical efficacy and safety comparison of CD3 bispecific and ADC modalities targeting BCMA for the treatment of multiple myeloma","volume":"18","author":"Panowski","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clbc.2026.01.004_bib0066","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1007\/s00432-023-04805-z","article-title":"mRNA vaccination in breast cancer: current progress and future direction","volume":"149","author":"Jiang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clbc.2026.01.004_bib0067","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12672-025-02542-y","article-title":"Advances in mRNA vaccine therapy for breast cancer research","volume":"16","author":"Li","year":"2025","journal-title":"Discov Oncol"},{"key":"10.1016\/j.clbc.2026.01.004_bib0068","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials of mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2026.01.004_bib0069","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3390\/bioengineering11040322","article-title":"AutoEpiCollect, a novel machine learning-based GUI software for vaccine design: application to pan-cancer vaccine design targeting PIK3CA neoantigens","volume":"11","author":"Samudrala","year":"2024","journal-title":"Bioengineering"},{"key":"10.1016\/j.clbc.2026.01.004_bib0070","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010569","article-title":"Leveraging mRNA technology for antigen based immuno-oncology therapies","volume":"13","author":"Floudas","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clbc.2026.01.004_bib0071","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1016\/j.csbj.2023.10.050","article-title":"SIGANEO: similarity network with GAN enhancement for immunogenic neoepitope prediction","volume":"21","author":"Ye","year":"2023","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.clbc.2026.01.004_bib0072","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymthe.2017.10.020","article-title":"Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer","volume":"26","author":"Liu","year":"2018","journal-title":"Mole Ther"},{"key":"10.1016\/j.clbc.2026.01.004_bib0073","article-title":"Targeting lymph nodes for enhanced cancer vaccination: from nanotechnology to tissue engineering","volume":"26","author":"Wang","year":"2024","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.clbc.2026.01.004_bib0074","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12951-023-01977-1","article-title":"Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions","volume":"21","author":"Li","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.clbc.2026.01.004_bib0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00262-018-2238-5","article-title":"An autologous dendritic cell vaccine polarizes a Th-1 response which is tumoricidal to patient-derived breast cancer cells","volume":"68","author":"Tomasicchio","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clbc.2026.01.004_bib0076","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3390\/vaccines12091058","article-title":"Anti-tumor immunity to patient-derived breast cancer Cells by vaccination with interferon-alpha-conditioned dendritic cells (IFN-DC)","volume":"12","author":"Lapenta","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.clbc.2026.01.004_bib0077","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1779991","article-title":"Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy","volume":"9","author":"Naseri","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clbc.2026.01.004_bib0078","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/vaccines13040344","article-title":"Advancing breast cancer treatment: the role of immunotherapy and cancer vaccines in overcoming therapeutic challenges","volume":"13","author":"Palma","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.clbc.2026.01.004_bib0079","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.3390\/cancers13194883","article-title":"Immunomodulating therapies in breast cancer\u2014from prognosis to clinical practice","volume":"13","author":"Schmidt","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.clbc.2026.01.004_bib0080","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1080\/21645515.2020.1754691","article-title":"Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer","volume":"16","author":"Pack","year":"2020","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.clbc.2026.01.004_bib0081","doi-asserted-by":"crossref","DOI":"10.1172\/JCI164258","article-title":"Linked CD4+\/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression","volume":"133","author":"Dolina","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clbc.2026.01.004_bib0082","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","article-title":"Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity","volume":"186","author":"Ma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.clbc.2026.01.004_bib0083","doi-asserted-by":"crossref","first-page":"xii11","DOI":"10.1093\/annonc\/mdx681","article-title":"Preclinical and clinical development of neoantigen vaccines","volume":"28","author":"Li","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.01.004_bib0084","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007336","article-title":"Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer","volume":"11","author":"Brito Baleeiro","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clbc.2026.01.004_bib0085","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2021.10.027","article-title":"Therapeutic vaccines for breast cancer: Has the time finally come?","volume":"160","author":"Corti","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2026.01.004_bib0086","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188831","article-title":"Chimeric RNAs reveal putative neoantigen peptides for developing tumor vaccines for breast cancer","volume":"14","author":"Mistretta","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.clbc.2026.01.004_bib0087","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/cancers8060056","article-title":"Targeted vaccination against human \u03b1-lactalbumin for immunotherapy and primary immunoprevention of triple negative breast cancer","volume":"8","author":"Tuohy","year":"2016","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2026.01.004_bib0088","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41587-020-0697-7","article-title":"Whither COVID-19 vaccines?","volume":"38","author":"DeFrancesco","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clbc.2026.01.004_bib0089","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.584367","article-title":"Enhancing the efficacy of tumor vaccines based on immune evasion mechanisms","volume":"10","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2026.01.004_bib0090","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3390\/cancers16081483","article-title":"Targeting pivotal hallmarks of cancer for enhanced therapeutic strategies in triple-negative breast cancer treatment\u2014in vitro, in vivo and clinical trials literature review","volume":"16","author":"Szulc","year":"2024","journal-title":"Cancers"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:37:48Z","timestamp":1773405468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1526820926000054"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.01.004","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breast Cancer Vaccines: A Review of Emerging Opportunities and Persistent Challenges","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}